Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation. 2011

Barbara Alicja Jereczek-Fossa, and Dario Zerini, and Cristiana Fodor, and Luigi Santoro, and Raffaella Cambria, and Cristina Garibaldi, and Barbara Tagaste, and Andrea Vavassori, and Federica Cattani, and Daniela Alterio, and Federica Gherardi, and Flavia Serafini, and Bernardo Rocco, and Gennaro Musi, and Ottavio De Cobelli, and Roberto Orecchia
Department of Radiation Oncology, European Institute of Oncology, Milan, Italy. barbara.jereczek@ieo.it

OBJECTIVE To compare acute toxicity of prostate cancer image-guided hypofractionated radiotherapy (hypo-IGRT) with conventional fractionation without image-guidance (non-IGRT). To test the hypothesis that the potentially injurious effect of hypofractionation can be counterbalanced by the reduced irradiated normal tissue volume using IGRT approach. METHODS One hundred seventy-nine cT1-T2N0M0 prostate cancer patients were treated within the prospective study with 70.2 Gy/26 fractions (equivalent to 84 Gy/42 fractions, α/β 1.5 Gy) using IGRT (transabdominal ultrasound, ExacTrac X-Ray system, or cone-beam computer tomography). Their prospectively collected data were compared with data of 174 patients treated to 80 Gy/40 fractions with non-IGRT. The difference between hypo-IGRT and non-IGRT cohorts included fractionation (hypofractionation vs. conventional fractionation), margins (hypo-IGRT margins: 7 mm and 3 mm, for all but posterior margins; respectively; non-IGRT margins: 10 and 5 mm, for all but posterior margins, respectively), and use of image-guidance or not. Multivariate analysis was performed to define the tumor-, patient-, and treatment-related predictors for acute toxicity. RESULTS All patients completed the prescribed radiotherapy course. Acute toxicity in the hypo-IGRT cohort included rectal (G1: 29.1%; G2: 11.2%; G3: 1.1%) and urinary events (G1: 33.5%; G2: 39.1%; G3: 5%). Acute toxicity in the non-IGRT patients included rectal (G1: 16.1%; G2: 6.3%) and urinary events (G1: 36.2%; G2: 20.7%; G3: 0.6%). In 1 hypo-IGRT and 2 non-IGRT patients, radiotherapy was temporarily interrupted due to acute toxicity. The incidence of mild (G1-2) rectal and bladder complications was significantly higher for hypo-IGRT (P = 0.0014 and P < 0.0001, respectively). Multivariate analysis showed that hypo-IGRT (P = 0.001) and higher PSA (P = 0.046) are correlated with higher acute urinary toxicity. No independent factor was identified for acute rectal toxicity. No significant impact of IGRT system on acute toxicity was observed. CONCLUSIONS The acute toxicity rates were low and similar in both study groups with some increase in mild acute urinary injury in the hypo-IGRT patients (most probably due to the under-reporting in the retrospectively analyzed non-IGRT cohort). The higher incidence of acute bowel reactions observed in hypo-IGRT group was not significant in the multivariate analysis. Further investigation is warranted in order to exclude the bias due to the nonrandomized character of the study.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011832 Radiation Injuries Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES. Radiation Sickness,Radiation Syndrome,Injuries, Radiation,Injury, Radiation,Radiation Injury,Radiation Sicknesses,Radiation Syndromes,Sickness, Radiation,Sicknesses, Radiation,Syndrome, Radiation,Syndromes, Radiation
D011880 Radiotherapy Planning, Computer-Assisted Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy. Computer-Assisted Radiotherapy Planning,Dosimetry Calculations, Computer-Assisted,Planning, Computer-Assisted Radiotherapy,Calculation, Computer-Assisted Dosimetry,Calculations, Computer-Assisted Dosimetry,Computer Assisted Radiotherapy Planning,Computer-Assisted Dosimetry Calculation,Computer-Assisted Dosimetry Calculations,Dosimetry Calculation, Computer-Assisted,Dosimetry Calculations, Computer Assisted,Planning, Computer Assisted Radiotherapy,Radiotherapy Planning, Computer Assisted
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Barbara Alicja Jereczek-Fossa, and Dario Zerini, and Cristiana Fodor, and Luigi Santoro, and Raffaella Cambria, and Cristina Garibaldi, and Barbara Tagaste, and Andrea Vavassori, and Federica Cattani, and Daniela Alterio, and Federica Gherardi, and Flavia Serafini, and Bernardo Rocco, and Gennaro Musi, and Ottavio De Cobelli, and Roberto Orecchia
November 2008, International journal of radiation oncology, biology, physics,
Barbara Alicja Jereczek-Fossa, and Dario Zerini, and Cristiana Fodor, and Luigi Santoro, and Raffaella Cambria, and Cristina Garibaldi, and Barbara Tagaste, and Andrea Vavassori, and Federica Cattani, and Daniela Alterio, and Federica Gherardi, and Flavia Serafini, and Bernardo Rocco, and Gennaro Musi, and Ottavio De Cobelli, and Roberto Orecchia
April 2018, International journal of clinical oncology,
Barbara Alicja Jereczek-Fossa, and Dario Zerini, and Cristiana Fodor, and Luigi Santoro, and Raffaella Cambria, and Cristina Garibaldi, and Barbara Tagaste, and Andrea Vavassori, and Federica Cattani, and Daniela Alterio, and Federica Gherardi, and Flavia Serafini, and Bernardo Rocco, and Gennaro Musi, and Ottavio De Cobelli, and Roberto Orecchia
August 2009, International journal of radiation oncology, biology, physics,
Barbara Alicja Jereczek-Fossa, and Dario Zerini, and Cristiana Fodor, and Luigi Santoro, and Raffaella Cambria, and Cristina Garibaldi, and Barbara Tagaste, and Andrea Vavassori, and Federica Cattani, and Daniela Alterio, and Federica Gherardi, and Flavia Serafini, and Bernardo Rocco, and Gennaro Musi, and Ottavio De Cobelli, and Roberto Orecchia
April 2015, Current oncology (Toronto, Ont.),
Barbara Alicja Jereczek-Fossa, and Dario Zerini, and Cristiana Fodor, and Luigi Santoro, and Raffaella Cambria, and Cristina Garibaldi, and Barbara Tagaste, and Andrea Vavassori, and Federica Cattani, and Daniela Alterio, and Federica Gherardi, and Flavia Serafini, and Bernardo Rocco, and Gennaro Musi, and Ottavio De Cobelli, and Roberto Orecchia
January 2014, BioMed research international,
Barbara Alicja Jereczek-Fossa, and Dario Zerini, and Cristiana Fodor, and Luigi Santoro, and Raffaella Cambria, and Cristina Garibaldi, and Barbara Tagaste, and Andrea Vavassori, and Federica Cattani, and Daniela Alterio, and Federica Gherardi, and Flavia Serafini, and Bernardo Rocco, and Gennaro Musi, and Ottavio De Cobelli, and Roberto Orecchia
June 2008, International journal of radiation oncology, biology, physics,
Barbara Alicja Jereczek-Fossa, and Dario Zerini, and Cristiana Fodor, and Luigi Santoro, and Raffaella Cambria, and Cristina Garibaldi, and Barbara Tagaste, and Andrea Vavassori, and Federica Cattani, and Daniela Alterio, and Federica Gherardi, and Flavia Serafini, and Bernardo Rocco, and Gennaro Musi, and Ottavio De Cobelli, and Roberto Orecchia
June 2016, Chinese medical journal,
Barbara Alicja Jereczek-Fossa, and Dario Zerini, and Cristiana Fodor, and Luigi Santoro, and Raffaella Cambria, and Cristina Garibaldi, and Barbara Tagaste, and Andrea Vavassori, and Federica Cattani, and Daniela Alterio, and Federica Gherardi, and Flavia Serafini, and Bernardo Rocco, and Gennaro Musi, and Ottavio De Cobelli, and Roberto Orecchia
April 2013, Radiation oncology (London, England),
Barbara Alicja Jereczek-Fossa, and Dario Zerini, and Cristiana Fodor, and Luigi Santoro, and Raffaella Cambria, and Cristina Garibaldi, and Barbara Tagaste, and Andrea Vavassori, and Federica Cattani, and Daniela Alterio, and Federica Gherardi, and Flavia Serafini, and Bernardo Rocco, and Gennaro Musi, and Ottavio De Cobelli, and Roberto Orecchia
March 2024, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Barbara Alicja Jereczek-Fossa, and Dario Zerini, and Cristiana Fodor, and Luigi Santoro, and Raffaella Cambria, and Cristina Garibaldi, and Barbara Tagaste, and Andrea Vavassori, and Federica Cattani, and Daniela Alterio, and Federica Gherardi, and Flavia Serafini, and Bernardo Rocco, and Gennaro Musi, and Ottavio De Cobelli, and Roberto Orecchia
October 2011, Radiation oncology (London, England),
Copied contents to your clipboard!